1. Home
  2. PROK vs TATT Comparison

PROK vs TATT Comparison

Compare PROK & TATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • TATT
  • Stock Information
  • Founded
  • PROK 2015
  • TATT 1985
  • Country
  • PROK United States
  • TATT Israel
  • Employees
  • PROK N/A
  • TATT N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • TATT Aerospace
  • Sector
  • PROK Health Care
  • TATT Industrials
  • Exchange
  • PROK Nasdaq
  • TATT Nasdaq
  • Market Cap
  • PROK 384.2M
  • TATT 384.2M
  • IPO Year
  • PROK N/A
  • TATT 1987
  • Fundamental
  • Price
  • PROK $2.35
  • TATT $36.18
  • Analyst Decision
  • PROK Buy
  • TATT Strong Buy
  • Analyst Count
  • PROK 5
  • TATT 3
  • Target Price
  • PROK $6.25
  • TATT $37.00
  • AVG Volume (30 Days)
  • PROK 3.3M
  • TATT 161.5K
  • Earning Date
  • PROK 08-12-2025
  • TATT 08-11-2025
  • Dividend Yield
  • PROK N/A
  • TATT N/A
  • EPS Growth
  • PROK N/A
  • TATT 62.92
  • EPS
  • PROK N/A
  • TATT 1.19
  • Revenue
  • PROK $527,000.00
  • TATT $166,749,000.00
  • Revenue This Year
  • PROK $105.79
  • TATT $22.42
  • Revenue Next Year
  • PROK N/A
  • TATT $18.78
  • P/E Ratio
  • PROK N/A
  • TATT $28.40
  • Revenue Growth
  • PROK N/A
  • TATT 25.96
  • 52 Week Low
  • PROK $0.46
  • TATT $14.00
  • 52 Week High
  • PROK $7.13
  • TATT $38.26
  • Technical
  • Relative Strength Index (RSI)
  • PROK 43.77
  • TATT 53.21
  • Support Level
  • PROK $2.16
  • TATT $30.36
  • Resistance Level
  • PROK $2.46
  • TATT $35.73
  • Average True Range (ATR)
  • PROK 0.34
  • TATT 2.01
  • MACD
  • PROK -0.16
  • TATT -0.29
  • Stochastic Oscillator
  • PROK 7.14
  • TATT 51.46

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About TATT TAT Technologies Ltd.

TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.

Share on Social Networks: